Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 15:16:1539659.
doi: 10.3389/fimmu.2025.1539659. eCollection 2025.

A possible role for immunogenetic factors in myositis developing after vaccination in the pre-covid-19 era

Eaman Alhassan #  1 , Anna Patnaik #  2   3 , Ejaz A Shamim #  3   4   5 , Janardan P Pandey  6 , Lisa G Rider #  3 , Frederick W Miller #  3   7
Affiliations

A possible role for immunogenetic factors in myositis developing after vaccination in the pre-covid-19 era

Eaman Alhassan et al. Front Immunol. .

Abstract

Introduction: Vaccinations have had a transformative impact on public health, reducing the incidence of many infectious diseases and increasing survival. However, there remains uncertainty about the potential of vaccines to trigger autoimmune diseases such as the idiopathic inflammatory myopathies (IIM). Myositis after vaccination (MAV) is a rare clinical entity, but given immunogenetic associations with other adverse events, we explored genetic risk factors, particularly human leukocyte antigen (HLA) alleles and GM/KM immunoglobulin allotypes, that may predispose individuals to develop MAV.

Methods: We examined clinical characteristics, vaccination history, autoantibodies, HLA alleles and GM/KM allotypes from 56 patients who developed MAV, 133 myositis cases with no documented vaccination within 6 months of onset (non-MAV), and 527 healthy controls from the pre-COVID-19 era. Genotyping for HLA and GM/KM allotypes was performed by standard assays. Differences in allele frequencies in race-matched groups were evaluated using chi-square tests, odds ratios (OR) and 95% confidence intervals (CI). Multivariate logistic regression adjusted for age, sex, and vaccination type. Statistical significance was defined as a Holms corrected p-value of less than 0.05.

Results: No clinical or serologic differences were found between MAV and non-MAV patients. However, the HLA-DQA1*03:03 allele was a unique risk factor for MAV in Caucasians (OR=3.87, 95% CI=1.56-9.54, p=0.002), while the known myositis risk factor, HLA-DRB1*03:01, was a protective factor for MAV (OR=0.41, 95% CI=0,18-0.94, p= 0.033). GM2, GM13, and KM1 allotypes were more frequently observed in MAV patients than healthy controls, and other HLA alleles were risk or protective factors for specific vaccines given in patients who developed MAV.

Conclusion: Immunogenetic factors may influence the likelihood of developing MAV. Further studies of larger, deeply phenotyped populations are needed to confirm these associations and could inform personalized risk assessments and targeted interventions, thereby enhancing vaccine safety.

Keywords: GM/KM; HLA; adverse events; dermatomyositis; juvenile dermatomyositis; polymyositis; vaccination.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

References

    1. Miller FW, Lamb JA, Schmidt J, Nagaraju K. Risk factors and disease mechanisms in myositis. Nat Rev Rheumatol. (2018) 14:255–68. doi: 10.1038/nrrheum.2018.48, PMID: - DOI - PMC - PubMed
    1. Caliskan M, Brown CD, Maranville JC. A catalog of GWAS fine-mapping efforts in autoimmune disease. Am J Hum Genet. (2021) 108:549–63. doi: 10.1016/j.ajhg.2021.03.009, PMID: - DOI - PMC - PubMed
    1. Miller FW. Environment, lifestyles, and climate change: the many nongenetic contributors to the long and winding road to autoimmune diseases. Arthritis Care Res (Hoboken). (2024) 77(1):3–11. doi: 10.1002/acr.25423, PMID: - DOI - PMC - PubMed
    1. Toussirot É, Bereau M. Vaccination and induction of autoimmune diseases. Inflammation Allergy Drug Targets. (2015) 14:94–8. doi: 10.2174/1871528114666160105113046, PMID: - DOI - PubMed
    1. Shumnalieva R, Ravichandran N, Hannah J, Javaid M, Darooka N, Roy D, et al. Characteristics of emerging new autoimmune diseases after COVID-19 vaccination: A sub-study by the COVAD group. Int J Rheum Dis. (2024) 27:e15178. doi: 10.1111/1756-185X.15178, PMID: - DOI - PubMed

MeSH terms